Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation

Condition(s) studied

Investigational drug(s) / intervention(s)

Blood samples (additional tubes from care) longitudinal: Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).

Blood samples (additional tubes from care) at inclusion: In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made. In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification.

Study summary

Description of the evolution of the biological characteristics of immune blood populations and biomarkers of interest in patients who have received allogeneic hematopoietic stem cell transplantation.

Eligibility

Primary outcome measure(s)

• Evolution of the immune blood populations in patients who have received allogeneic hematopoietic stem cell transplantation. — 5 years after HSC transplantation
  longitudinal study of the immune subpopulations of allografted patients for hematological malignancies.

Trial sites (1)

More Institut Paoli-Calmettes trials in France

Other trials for the same condition